You are here

obesity

AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug

Fierce Biotech

Thu, 11/9/23 - 09:58 am

sickle cell disease

An obesity drug biotech gets buy-in from Eli Lilly, venture firms

BioPharma Dive

Tue, 11/7/23 - 09:50 am

'This field is in its infancy': Amgen noncommittal on oral obesity med until phase 1 data arrive

Fierce Biotech

Wed, 11/1/23 - 10:17 am

Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro

Stat

Thu, 10/26/23 - 11:24 am

GE HealthCare, Novo Nordisk partner to treat diabetes and obesity with ultrasound

Mass Device

Fri, 10/20/23 - 10:14 am

type 2 diabetes

Eli Lilly plans diabetes drug trial for kids as young as 6 years - Bloomberg

Yahoo/Reuters

Fri, 10/20/23 - 10:02 am

clinical trials

Boehringer moves obesity therapy into phase 3

Pharmaphorum

Fri, 10/6/23 - 10:01 am

Boehringer Ingelheim

clinical trials

Structure Therapeutics surges on promising early stage obesity drug data

Reuters

Fri, 09/29/23 - 10:21 am

Structure Therapeutics

clinical trials

Obesity Drug Market Set to Hit $100 Billion by 2035, BMO Says

Yahoo/Bloomberg

Sun, 09/24/23 - 08:56 pm

Altimmune completes dosing in MOMENTUM trial to treat obesity

Clinical Trials Arena

Wed, 09/13/23 - 11:15 am

clinical trials

Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan

Fierce Pharma

Mon, 09/11/23 - 12:26 pm

Novo Nordisk Is Already Working on Ozempic 2.0

Motley Fool

Thu, 09/7/23 - 10:12 am

Novo Nordisk launches Wegovy for obese patients in UK

Pharmaceutical Business Review

Tue, 09/5/23 - 11:25 am

Competing in These 3 Markets Could Send Eli Lilly Stock Soaring

Motley Fool

Tue, 09/5/23 - 11:23 am

Alzheimer's disease

Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins

Clinical Trials Arena

Thu, 08/31/23 - 06:02 pm

clinical trials

type 2 diabetes

Novo Bolsters Obesity Pipeline with Potential $500M Embark Biotech Buy

BioSpace

Wed, 08/30/23 - 11:22 am

Boehringer preps phase 3 for dual-action obesity drug

Pharmaphorum

Thu, 08/17/23 - 09:54 am

Boehringer Ingelheim

clinical trials

Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to front of pharma's growth pack in Q2

Fierce Pharma

Wed, 08/16/23 - 10:05 am

Novo Nordisk bets $1.1B on Canadian biotech buyout, adding an old approach to obesity pipeline

Fierce Biotech

Thu, 08/10/23 - 11:41 am

In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

Pharma Voice

Wed, 08/9/23 - 10:14 am

Pages